Celularity Inc (CELU) Stock Price & Analysis
Celularity Inc (CELU) rose 1.67% to USD 0.7 as of June 10, 2026 at 14:32 UTC, according to Nexqual real-time market data.
CELU last closed at USD 0.69; the session ranged USD 0.69–0.73 on volume of 8,171 shares. Market capitalization is $20.26M, with a 52-week range of USD 0.69–4.35 (NCM). Source: Nexqual, June 10, 2026 at 14:32 UTC.
Key Statistics (as of June 10, 2026 at 14:32 UTC)
| Price | USD 0.7 |
|---|---|
| Change | ▲ 1.67% (up) |
| Previous Close | USD 0.69 |
| Open | USD 0.69 |
| Day Range | USD 0.69 – 0.73 |
| 52-Week Range | USD 0.69 – 4.35 |
| Volume | 8,171 shares |
| Market Cap | $20.26M |
| Exchange | NCM |
Technical Analysis (CELU)
Nexqual's technical model rates CELU "SELL" based on 2 bullish and 5 bearish signals across 125 daily candles, as of June 10, 2026 at 14:32 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.94 (oversold) |
| vs SMA50 | Below (USD 1.03) |
| MACD | -0.05 (negative) |
Analyst Ratings (CELU)
Wall Street analysts rate CELU "None", per Nexqual as of June 10, 2026 at 14:32 UTC.
| Consensus Rating | None |
|---|
Earnings (CELU)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2023-06-30 | USD -2.7 vs est -0.3 ▼ miss |
| 2023-03-31 | USD -4.1 vs est -2.4 ▼ miss |
Source: Nexqual, June 10, 2026 at 14:32 UTC.
Financials & Fundamentals (CELU)
| Total Revenue | $26.55M |
|---|---|
| Revenue Growth (YoY) | -77.40% |
| Gross Margin | +24.39% |
| Operating Margin | -492.15% |
| Profit Margin | +0.00% |
| Current Ratio | 0.15 |
| Total Cash | $6.17M |
| Total Debt | $74.71M |
| Free Cash Flow | $5.38M |
Source: Nexqual, June 10, 2026 at 14:32 UTC.
Financial Health Score (CELU)
Nexqual rates Celularity Inc's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 14:32 UTC.
| Growth | Critical — Revenue -100% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $6M cash vs $75M debt |
| Cash Flow | Weak — Operating cash flow -$13M |
| Efficiency | Mixed — No data |
Ownership (CELU)
| Insider Ownership | +37.18% |
|---|---|
| Institutional Ownership | +12.77% |
| Shares Outstanding | 28.95M |
| Float | 18.87M |
| Short % of Float | +5.18% |
Source: Nexqual, June 10, 2026 at 14:32 UTC.
Leadership (CELU)
Celularity Inc is led by Robert Joseph Hariri (age 66), Founder, CEO & Chairman, per Nexqual as of June 10, 2026 at 14:32 UTC.
| Founder, CEO & Chairman | Robert Joseph Hariri (age 66) |
|---|---|
| Acting Chief Financial Officer | John Sprague |
| Senior Vice President of Clinical Dev. Immunology & Drug Safety | Sharmila Koppisetti |
| Senior Vice President of Technical Operations | Tim Wilk |
Major Backers & Investors (CELU)
Notable institutional backers of Celularity Inc include C V STARR & CO INC, Fidelity, ValMark Advisers, Inc., according to Nexqual as of June 10, 2026 at 14:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| C V STARR & CO INC | 2.64% |
| Fidelity | 0.53% |
| ValMark Advisers, Inc. | 0.17% |
| HB Wealth Management, LLC | 0.14% |
| Biltmore Family Office, LLC | 0.12% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 4.57% |
| Geode Capital | 0.66% |
| BlackRock | 0.61% |
| State Street | 0.2% |
| Northern Trust | 0.15% |
Source: Nexqual, June 10, 2026 at 14:32 UTC.
From Celularity Inc's Latest SEC 10-K Filing (filed 2026-04-30)
Key Strengths & Strategy (as disclosed to the SEC)
- We have developed and acquired proprietary technology for collecting, processing, and storing placental stem cells with potentially broad therapeutic applications in the treatment of aging-associated and other degenerative disorders and diseases.
- Utilizing our Celularity IMPACT platform, our proprietary process has mitigated these limitations by expanding and differentiating placental-derived stem cells into NK cells over a period of 35 days.
- We use our proprietary Celularity IMPACT platform for the development of allogeneic cellular therapies that we believe exert immunomodulatory and regenerative effects.
- Donors providing birth materials do not encounter any fees and are not renumerated.   Licensed health care professionals collect donor material utilizing our proprietary collection kits, which include barcode labels for biomaterials (cord blood, placenta, and maternal blood samples) along with appropriate chain of custody documentation.
Partnerships
- Hoffmann-La Roche AG.   Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| ENSC | Ensysce Biosciences, Inc. | USD 0.25 | ▼ 2.37% |
| BTTX | Better Therapeutics, Inc. | USD 0 | ▲ 0% |
| CLNN | Clene Inc. | USD 5.52 | ▲ 3.56% |
| EFTR | eFFECTOR Therapeutics, Inc. | USD 0 | ▲ 0% |
| INAB | IN8bio, Inc. | USD 1.48 | ▲ 2.78% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 14:32 UTC. This page is informational and not investment advice.